Post-Myocardial Infarction Heart Failure

JACC. Heart Failure
M Cecilia BahitChristopher B Granger

Abstract

Heart failure (HF) complicating myocardial infarction (MI) is common and may be present at admission or develop during the hospitalization. Among patients with MI, there is a strong relationship between degree of HF and mortality. The optimal management of the patient with HF complicating MI varies according to time since the onset of infarction. Medical therapy for HF after MI includes early (within 24 h) initiation of angiotensin-converting enzyme inhibitors and early (within 7 days) use of aldosterone antagonists. Alternatively, in patients with MI and ongoing HF, early use (<24 h) of beta-blockers is associated with an increased risk of cardiogenic shock and death. Long-term beta-blocker use after MI is associated with a reduced risk of reinfarction and death. Thus, it is critical to frequently re-evaluate beta-blocker eligibility among patients after MI with HF. Cardiogenic shock is an extreme presentation of HF after MI and is a leading cause of death in the MI setting. The only therapy proven to reduce mortality for patients with cardiogenic shock is early revascularization. Several studies are examining new approaches to mitigate the occurrence and adverse impact of post-MI HF. These studies are testing drugs for HF and...Continue Reading

Citations

Feb 28, 2019·Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions·Varunsiri AttiDeepak L Bhatt
May 30, 2019·Journal of Biomechanical Engineering·Colleen Witzenburg, Jeffrey W Holmes
Nov 26, 2019·European Heart Journal. Acute Cardiovascular Care·Bartosz HudzikMariusz Gąsior
Apr 17, 2020·Journal of Cellular and Molecular Medicine·Rolf SchreckenbergKlaus-Dieter Schlüter
May 12, 2020·Journal of the American Heart Association·Roberta FloridoChiadi E Ndumele
Oct 28, 2019·Circulation Research·Hsiao-Yun Y MillironStefan Jovinge
Jun 23, 2020·Cardiovascular Therapeutics·Ginenus FekaduMudasir Maqbool
Jun 12, 2020·Current Heart Failure Reports·Andrew XanthopoulosFilippos Triposkiadis
Feb 8, 2019·The Journal of Pharmacology and Experimental Therapeutics·Laura SaludasMaría J Blanco-Prieto
Nov 5, 2019·Frontiers in Immunology·Helong DaiNatasha M Rogers
May 23, 2020·Journal of Cardiovascular Translational Research·Li YanZhi-Ru Ge
Nov 6, 2018·Journal of Clinical Medicine·Mona PanahiSusanne Sattler
Dec 11, 2020·Circulation. Cardiovascular Imaging·Victor Marcos-GarcesVicente Bodi
Dec 29, 2020·Cardiovascular Revascularization Medicine : Including Molecular Interventions·Diala A SteitiehNivee P Amin
Feb 9, 2021·Cardiovascular Drugs and Therapy·Wangde DaiRobert A Kloner
Mar 9, 2021·Oxidative Medicine and Cellular Longevity·Shuang Ling, Jin-Wen Xu
Apr 11, 2021·European Journal of Preventive Cardiology·Yoshihiro Fukumoto
Aug 30, 2020·The Journal of Thoracic and Cardiovascular Surgery·Matthew L Goodwin, Craig H Selzman
Aug 14, 2019·Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine·Zohreh VarastehWolfgang A Weber
Apr 13, 2021·American Journal of Physiology. Heart and Circulatory Physiology·Cesar Rios-NavarroVicente Bodi
Jun 25, 2021·Cardiovascular Research·Katherine M Ross StewartMairi Brittan
Aug 4, 2021·Experimental Biology and Medicine·Jingxian XingTao Geng
Jul 7, 2021·Expert Review of Cardiovascular Therapy·Vassili PanagidesJosep Rodes-Cabau

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiogenic Shock

Cardiogenic shock is a devastating consequence of acute myocardial infarction and is associated with an extremely high mortality. Here is the latest research.